X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Sandoz will access US biosimilar Cimerli (ranibizumab) from Coherus. Currently used in the treatment of Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: Cimerli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: $170.0 million Upfront Cash: $170.0 million
Deal Type: Divestment March 04, 2024
Details:
Udenyca Onbody, the company's on-body injector (OBI) presentation of Udenyca® (pegfilgrastim-cbqv), a CSF-3R agonist. It is indicated for the treatment of decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies.
Lead Product(s): Pegfilgrastim
Therapeutic Area: Hematology Product Name: Udenyca Onbody
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
Through the acquisition, Sandoz will access US biosimilar Cimerli (ranibizumab) from Coherus. Currently used in the treatment of Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: Cimerli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: $170.0 million Upfront Cash: $170.0 million
Deal Type: Divestment January 22, 2024
Details:
The collaboration aims to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi), supplied by Coherus, as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC).
Lead Product(s): INO-3112,Toripalimab
Therapeutic Area: Oncology Product Name: INO-3112
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Inovio Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
Loqtorzi (toripalimab-tpzi) is a PD-1 receptor inhibitor, enabling the immune system to activate and kill the tumor. It is approved for the first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Udenyca (pegfilgrastim-cbqv), is a FDA-approved biosimilar that acts as a G-CSF agonist for the treatment of patients with non-myeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Lead Product(s): Pegfilgrastim
Therapeutic Area: Hematology Product Name: Udenyca
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
Loqtorzi (toripalimab-tpzi) is a PD-1 receptor inhibitor, enabling the immune system to activate and kill the tumor. It is approved for the first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy.
Lead Product(s): Toripalimab-tpzi,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Loqtorzi (toripalimab-tpzi) is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD-1 receptor at a unique site with high affinity and activates antitumor immunity. It is approved for treatment of recurrent/metastatic nasopharyngeal carcinoma.
Lead Product(s): Toripalimab
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2023
Details:
Udenyca Onbody (pegfilgrastim-cbqv) Autoinjector products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Lead Product(s): Pegfilgrastim
Therapeutic Area: Hematology Product Name: Udenyca Onbody
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
Cimerli (ranibizumab-eqrn), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the neovascular (Wet) Age-Related Macular Degeneration.
Lead Product(s): Ranibizumab-eqrn
Therapeutic Area: Ophthalmology Product Name: Cimerli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
